Proteome Sciences Past Earnings Performance
Past criteria checks 0/6
Proteome Sciences's earnings have been declining at an average annual rate of -49.1%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 7.7% per year.
Key information
-49.1%
Earnings growth rate
-49.1%
EPS growth rate
| Life Sciences Industry Growth | 36.9% |
| Revenue growth rate | 7.7% |
| Return on equity | n/a |
| Net Margin | -101.1% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Here's Why Shareholders Should Examine Proteome Sciences plc's (LON:PRM) CEO Compensation Package More Closely
May 10
Here's Why We Think Proteome Sciences (LON:PRM) Is Well Worth Watching
Dec 02Here's Why Proteome Sciences (LON:PRM) Has Caught The Eye Of Investors
Aug 25Here's Why Proteome Sciences (LON:PRM) Has Caught The Eye Of Investors
Dec 22Do Proteome Sciences' (LON:PRM) Earnings Warrant Your Attention?
Sep 03Calculating The Fair Value Of Proteome Sciences plc (LON:PRM)
Jan 27Does Proteome Sciences (LON:PRM) Deserve A Spot On Your Watchlist?
May 31Some Confidence Is Lacking In Proteome Sciences plc's (LON:PRM) P/E
Apr 04Revenue & Expenses Breakdown
How Proteome Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 4 | -4 | 3 | 0 |
| 31 Mar 24 | 5 | -3 | 3 | 0 |
| 31 Dec 23 | 5 | -2 | 3 | 0 |
| 30 Sep 23 | 6 | -1 | 3 | 0 |
| 30 Jun 23 | 8 | 1 | 3 | 0 |
| 31 Mar 23 | 8 | 1 | 3 | 0 |
| 31 Dec 22 | 8 | 1 | 3 | 0 |
| 30 Sep 22 | 7 | 1 | 2 | 0 |
| 30 Jun 22 | 6 | 1 | 2 | 0 |
| 31 Mar 22 | 6 | 0 | 2 | 0 |
| 31 Dec 21 | 5 | 0 | 2 | 0 |
| 30 Sep 21 | 5 | 0 | 2 | 0 |
| 30 Jun 21 | 5 | 0 | 2 | 0 |
| 31 Mar 21 | 5 | 0 | 2 | 0 |
| 31 Dec 20 | 5 | 0 | 2 | 0 |
| 30 Sep 20 | 5 | 0 | 2 | 0 |
| 30 Jun 20 | 5 | 0 | 3 | 0 |
| 31 Mar 20 | 5 | 0 | 3 | 0 |
| 31 Dec 19 | 5 | 0 | 3 | 0 |
| 30 Sep 19 | 4 | 0 | 3 | 0 |
| 30 Jun 19 | 3 | 0 | 2 | 0 |
| 31 Mar 19 | 3 | -1 | 3 | 0 |
| 31 Dec 18 | 3 | -1 | 3 | 0 |
| 30 Sep 18 | 3 | -2 | 3 | 0 |
| 30 Jun 18 | 3 | -2 | 4 | 0 |
| 31 Mar 18 | 3 | -2 | 4 | 0 |
| 31 Dec 17 | 3 | -2 | 4 | 0 |
| 30 Sep 17 | 3 | -2 | 4 | 0 |
| 30 Jun 17 | 3 | -2 | 4 | 0 |
| 31 Mar 17 | 3 | -2 | 4 | 0 |
| 31 Dec 16 | 3 | -2 | 4 | 0 |
| 30 Sep 16 | 2 | -3 | 4 | 0 |
| 30 Jun 16 | 2 | -3 | 4 | 0 |
| 31 Mar 16 | 2 | -3 | 4 | 0 |
| 31 Dec 15 | 2 | -3 | 4 | 0 |
| 30 Sep 15 | 2 | -3 | 4 | 0 |
| 30 Jun 15 | 2 | -3 | 5 | 0 |
| 31 Mar 15 | 2 | -3 | 5 | 0 |
| 31 Dec 14 | 2 | -4 | 5 | 0 |
| 30 Sep 14 | 2 | -3 | 4 | 1 |
| 30 Jun 14 | 2 | -3 | 3 | 2 |
| 31 Mar 14 | 2 | -3 | 3 | 2 |
| 31 Dec 13 | 2 | -3 | 3 | 2 |
Quality Earnings: PRM is currently unprofitable.
Growing Profit Margin: PRM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PRM is unprofitable, and losses have increased over the past 5 years at a rate of 49.1% per year.
Accelerating Growth: Unable to compare PRM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PRM is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-0.7%).
Return on Equity
High ROE: PRM's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.